Arcus Biosciences is a clinical-stage biopharmaceutical company developing immuno-oncology therapies, including antibodies against targets such as TIGIT and PD-1. Its pipeline aims to improve cancer treatment through combination regimens and next-generation checkpoint approaches. A notable collaboration with Gilead Sciences supports late-stage development and commercialization of key candidates.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 160 | — | 0 | — |
| Q3 2025 | 26 | — | -135 | — |
| Q4 2025 | 33 | — | -106 | — |
| Q1 2026 | 17 | — | -128 | — |
| Q2 2026 | 41 | -74.4% | -91 | — |
All markets — KeepWinning global stock screener
Other companies on NYSE: Seabridge Gold Inc. (SA), Ardagh Metal Packaging S.A. (AMBP), IMAX Corporation (IMAX), Harley-Davidson, Inc. (HOG), Sprott Inc. (SII), H.B. Fuller Company (FUL)